Is there any evidence to support screening for and treating asymptomatic bacteruria for patient to undergo cardiothoracic surgery? Is there any data to support decreasing risk of future endocarditis?

Comment by InpharmD Researcher

Current guidelines recommend against routine screening for or treating asymptomatic bacteriuria (ASB) before elective nonurologic surgery, including cardiothoracic procedures. Available studies involving patients undergoing cardiac surgery, including coronary artery bypass grafting and valve replacement, have not demonstrated a significant reduction in postoperative infectious complications with preoperative ASB treatment. Although hematogenous dissemination of urinary pathogens is a potential concern, particularly in patients undergoing valve replacement or procedures involving prosthetic cardiac material, evidence demonstrating that preoperative ASB screening or treatment reduces the risk of subsequent infective endocarditis is lacking. Overall, the available evidence is predominantly observational and does not demonstrate a clinical benefit of routine preoperative ASB screening or treatment in cardiothoracic surgery; its potential impact on future infective endocarditis remains uncertain.

A literature search was conducted using PubMed and relevant clinical practice guidelines to identify evidence regarding preoperative screening for and treatment of asymptomatic bacteriuria in patients undergoing cardiothoracic surgery, including its impact on postoperative infectious complications and future infective endocarditis.

Background

According to the 2019 Infectious Diseases Society of America (IDSA) guidelines, routine screening for or treatment of asymptomatic bacteriuria (ASB) before elective nonurologic surgery, including cardiothoracic surgery, is not recommended (strong recommendation, low-quality evidence). This recommendation was informed by three studies involving 3,167 surgical patients, including patients undergoing cardiac and vascular procedures, of whom 403 (12.7%) had ASB. Approximately 47% of patients with ASB received targeted antimicrobial treatment in addition to perioperative prophylaxis. The guideline concluded that the benefit of treating ASB beyond standard perioperative prophylaxis remains highly uncertain, with very low certainty regarding effects on postoperative infectious outcomes. Additionally, evidence is insufficient to determine whether expanding perioperative prophylaxis to cover urinary pathogens provides additional benefit. The guideline does not specifically evaluate whether ASB screening or treatment reduces future infective endocarditis. [1]

According to the 2026 European Association of Urology (EAU) guidelines, screening for or treating ASB before cardiovascular surgery is not recommended (strong recommendation). This recommendation is supported by a 2018 systematic review and meta-analysis of three retrospective, nonrandomized studies involving 1,116 patients undergoing nonvalvular coronary artery bypass grafting (n= 473; 42%), valve replacement (n= 567; 51%), or thoracic aortic surgery (n= 76; 7%). Of these patients, 116 received targeted antimicrobial treatment for ASB before surgery. Surgical-site infections occurred more frequently among treated patients than untreated patients (12.9% vs 8.2%), although the difference was not statistically significant (p= 0.086). Similarly, the random-effects meta-analysis found no statistically significant reduction in infectious complications with ASB treatment (odds ratio [OR] 1.38; 95% confidence interval [CI] 0.56 to 3.38), with moderate heterogeneity across studies (I²= 64%). The guidelines acknowledge that the small number of studies, retrospective and nonrandomized designs, and heterogeneity limit the certainty of these findings. Importantly, the guidelines and the analysis did not specifically evaluate infective endocarditis as an outcome, and evidence demonstrating that preoperative ASB screening or treatment reduces the risk of future infective endocarditis is lacking. [2], [3]

Background References: [1] Nicolle LE, Gupta K, Bradley SF, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):e83-e110. doi:10.1093/cid/ciy1121
[2] European Association of Urology. EAU Guidelines on Urological Infections. EAU Guidelines Office; 2026. Accessed October 26, 2026.
[3] Gómez-Ochoa SA, Espín-Chico BB. Lack of Benefit on Treating Asymptomatic Bacteriuria Prior to Cardiovascular Surgery: a Systematic Review and Meta-Analysis. Braz J Cardiovasc Surg. 2018;33(6):641-643. doi:10.21470/1678-9741-2018-0276
Literature Review

A search of the published medical literature revealed 5 studies investigating the researchable question:

Is there any evidence to support screening for and treating asymptomatic bacteruria for patient to undergo cardiothoracic surgery? Is there any data to support decreasing risk of future endocarditis?

Level of evidence

C - Multiple studies with limitations or conflicting results  Read more→



Please see Tables 1-5 for your response.


Association of Screening and Treatment for Preoperative Asymptomatic Bacteriuria With Postoperative Outcomes Among US Veterans

Design

Retrospective cohort study

N= 68,265

Objective

To characterize the association between detection and treatment of preoperative asymptomatic bacteriuria (ASB) and postoperative outcomes

Study Groups

Preoperative urine culture screened (n= 17,749)

Preoperative ASB identified (n= 617)

Preoperative ASB not identified (n= 16,994)

Inclusion Criteria

Patients who underwent cardiac, orthopedic, or vascular surgical procedures with a preoperative urine culture result available within 30 days prior to the procedure

Exclusion Criteria

Not explicitly stated

Methods

Antimicrobial prophylaxis data and clinician-reviewed postoperative outcomes were obtained from VA programs. Preoperative urine screening was determined by facility and/or surgeon practice. Positive urine cultures were defined as ≥10⁵ CFU of any bacterial organism; other results were classified as negative. An infectious diseases physician reviewed positive cultures for documented urinary or systemic symptoms, with classification adjudicated by a second physician; positive cultures without documented symptoms were classified as ASB. Antimicrobials ordered between culture collection and surgery, and surgical prophylaxis, were classified as active or inactive according to organism identification and susceptibility; all isolates had to be susceptible for polymicrobial cultures to be considered actively treated. Active exposure did not necessarily reflect an intention to treat ASB. Associations were evaluated using logistic regression adjusted for patient characteristics and stratified by surgery type. All patients received surgical antimicrobial prophylaxis, although it was not necessarily active against the ASB organism.

Duration

October 1, 2008, to September 30, 2013

Outcome Measures

Primary: Association between preoperative ASB and postoperative SSI

Secondary: Postoperative UTI, association between antimicrobial therapy for ASB and postoperative infectious outcomes

Baseline Characteristics  

Preoperative Culture Screening - Not Performed 

Negative Result Positive Result - ASB Positive Result - Symptomatic
All patients

50,516

16,994 617 138
Male

96.7%

95.2% 87.4% 92.0%
Age, years

64.5 ± 9.1

64.8 ± 9.4 69.6 ± 10.4 71.5 ± 10.0
Diabetes

28.2%

24.9% 29.7% 31.9%
Current smoker

30.1%

25.5% 24.3% 24.6%

Surgical cohort

Cardiac

Orthopedic

Vascular

 

33.8%

52.0%

14.2%

 

24.0%

70.3%

5.7%

 

31.4%

60.9%

7.6%

 

34.8%

53.6%

11.6%

Results  

Preoperative ASB Not Identified (n = 16,994)

Preoperative ASB Identified (n = 617) aOR (95% CI) P Value

Whole cohort

SSI

UTI

 

268/16,994 (1.6%)

196/12,913 (1.5%)

 

15/617 (2.4%)

14/423 (3.3%)

 

1.58 (0.93-2.70)

1.42 (0.80-2.49)

0.08

Whole cohort

Positive wound culture result

Positive urine culture result

 

497/16,994 (2.9%)

616/16,994 (3.6%)

 

23/617 (3.7%)

83/617 (13.5%)

 

1.20 (0.78-1.85)

2.87 (2.28-3.70)

 

0.39

<0.001

In the cardiac surgery subgroup, preoperative ASB was associated with a higher incidence of 30-day SSI compared with a negative preoperative urine culture (6/194 [3.1%] vs 41/4,081 [1.0%]; adjusted odds ratio [aOR] 3.06; 95% confidence interval [CI] 1.27–7.30; p= 0.01) and positive postoperative urine cultures (31/194 [16.0%] vs 195/4,081 [4.8%]; aOR 3.11; 95% CI 2.04–4.74; p< 0.001), whereas positive wound cultures did not differ significantly (9/194 [4.6%] vs 149/4,081 [3.7%]; aOR 1.22; 95% CI 0.61–2.45; p= 0.57).

Among all 617 patients with ASB, 485 received antimicrobial therapy and/or surgical prophylaxis active against the urinary organism; active coverage was not associated with reduced SSI (2.5% vs 2.3%; aOR 1.01; 95% CI 0.28–3.65; p= 0.99), UTI (aOR 0.68; 95% CI 0.20–2.30; p= 0.54), positive wound cultures (aOR 0.71; 95% CI 0.27–1.86), or positive urine cultures (aOR 0.84; 95% CI 0.49–1.46).

Similarly, among cardiac surgery patients with ASB, SSI occurred in 5/152 (3.3%) receiving active coverage versus 1/42 (2.4%) without active coverage (aOR 1.71; 95% CI 0.17–16.34). Preoperative urinary organisms matched postoperative wound isolates in only 2/617 patients (0.3%), both involving Staphylococcus aureus. Postoperative UTI was not assessed in cardiac surgery patients, and endocarditis was not separately reported as an outcome.

Adverse Events

Not explicitly stated

Study Author Conclusions

The routine screening of preoperative urine cultures prior to major cardiac, orthopedic, and vascular surgical procedures rarely identified ASB in the predominantly male population of this study. When present, ASB was associated with high rates of positive urine culture results during the postoperative period. However, active antimicrobial therapy was not associated with a reduced incidence of postoperative SSIs or UTIs, indicating that ASB is a marker for host risk of colonization but not in the causal pathway of infections. To our knowledge, this study is the largest and most robust investigation into urine culture screening to date. It provides strong evidence that preoperative screening may not be valuable and should be discontinued as routine clinical practice.

Critique

This large, multicenter study used clinician-reviewed infection outcomes and organism-specific antimicrobial susceptibility data, but its observational design, predominantly male population, and few cardiac SSI events limit causal interpretation and precision. Although ASB was associated with increased SSI risk after cardiac surgery, active antimicrobial coverage was not associated with reduced SSI; endocarditis was not separately assessed, so this study cannot establish whether screening or treatment reduces future endocarditis risk.

Table 1 References:
[4] Gallegos Salazar J, O'Brien W, Strymish JM, Itani K, Branch-Elliman W, Gupta K. Association of Screening and Treatment for Preoperative Asymptomatic Bacteriuria With Postoperative Outcomes Among US Veterans. JAMA Surg. 2019;154(3):241-248. doi:10.1001/jamasurg.2018.4759
If you don’t test, they will not treat: Impact of stopping preoperative screening for asymptomatic bacteriuria
Design

Before-and-after intervention study

N= 502

Objective To assess the impact of removing routine urinalysis and urine culture from preoperative checklists for cardiac artery bypass grafting surgery on testing frequency, cost savings, antibiotic prescriptions, and postoperative infection rates
Study Groups

Preintervention group (n= 254)

Postintervention group (n= 248)

Inclusion Criteria Patients undergoing cardiac artery bypass grafting (CABG) surgery at Massachusetts General Hospital between May 2021 and June 2022
Exclusion Criteria Not specified
Methods Preoperative checklists were modified to remove routine urinalysis and urine culture. Data on urinalysis, urine culture, antibiotic prescriptions, and postoperative infections were collected from electronic medical records. Cost savings were estimated using the Centers for Medicare and Medicaid Services clinical laboratory fee schedule
Duration Preintervention: May 2021 to November 2021 Postintervention: December 2021 to May 2022
Outcome Measures

Primary: Reduction in urinalysis and urine culture testing

Secondary: Cost savings, reduction in antibiotic prescriptions, incidence of surgical-site infections, central line-associated bloodstream infection (CLABSIs), catheter-associated urinary tract infections (CAUTIs), and Clostridioides difficile infection (CDIs)

Baseline Characteristics   Preintervention (n= 254) Postintervention (n= 248)
Average age, years 67.7 66.4
Female 46 (18.1%) 35 (14.2%)
Male 208 (81.9%) 211 (85.8%)
Results   Preintervention Postintervention p-value
Urinalysis performed 97.2% 23.4% <0.0005
Urine cultures performed 92.9% 12.5% <0.0005
Antibiotic prescriptions for bacteriuria 9 4 0.11
Cost savings $0 $8,090.38 N/A

Following the intervention, preoperative urinalysis testing decreased by 76.5% (p<0.0005), with only 58 of 248 patients (23.4%) undergoing testing. Four patients had ASB, of whom three (75%) received targeted antibiotics. Postoperative infectious complications included 4 surgical-site infections, 1 CLABSI, 1 catheter-associated urinary tract infection (CAUTI), and 3 cases of CDI, compared with 10 SSIs, 1 CLABSI, and 2 CDI cases before the intervention. The intervention eliminated 190 urinalyses and 205 urine cultures, resulting in estimated total cost savings of $8,090.37. Overall, reducing routine preoperative urine testing was associated with fewer SSIs and lower laboratory costs, although the study does not establish a causal relationship between the intervention and postoperative infection outcomes.

Adverse Events No increase in surgical-site infections (SSIs), central-line–associated bloodstream infections (CLABSIs), CAUTIs, or Clostridioides difficile infections (CDIs) was observed.
Study Author Conclusions Removal of urinalysis and urine culture from preoperative checklists for cardiac surgery significantly reduced unnecessary testing and associated costs without increasing postoperative infection rates.
Critique The study effectively demonstrated the impact of removing unnecessary preoperative tests, leading to significant cost savings and reduced antibiotic prescriptions. However, the study's single-center design and reliance on electronic medical records for data collection may limit the generalizability of the findings. Additionally, the study was not powered to detect changes in postoperative infection rates or antibiotic use.
Table 2 References:
[5] Winkler ML, Huang J, Starr J, et al. If you don't test, they will not treat: Impact of stopping preoperative screening for asymptomatic bacteriuria. Antimicrob Steward Healthc Epidemiol. 2023;3(1):e95. Published 2023 May 26. doi:10.1017/ash.2023.166

Bacteriuria is not associated with surgical site infection in patients undergoing cardiovascular surgery

Design

Analytical study with a retrospective cohort

N= 840

Objective

To identify whether an association exists between the preoperative presence of asymptomatic bacteriuria or urinary tract infection (UTI) and surgical site infection (SSI) in patients undergoing cardiovascular surgery

Study Groups

Patients with asymptomatic bacteriuria (n= 33)

Patients with UTI (n= 13)

Patients without bacteriuria or UTI (n= 794)

Inclusion Criteria

Patients older than age 18 years who underwent myocardial revascularization or valve replacement surgery between March 2011 and April 2015

Exclusion Criteria

Patients who underwent other cardiovascular procedures, had incomplete data in their medical history, or lacked follow-up at 1 month postprocedure. Patients with active infection in any organ or tract other than the urinary tract were also excluded

Methods

Medical records, institutional SSI surveillance records, and microbiology databases were reviewed. ASB was defined as a urine culture yielding bacteria at a density of 10⁵ CFU/mL in a specimen collected using sterile technique from a patient without UTI signs or symptoms. Symptomatic UTI required a documented diagnosis, compatible symptoms, and a positive urine culture. Urine cultures were obtained according to physician indication or abnormal preoperative urinalysis findings rather than universally. Preoperative antibiotic exposure and treatment duration were recorded; all 13 patients with UTI and 7 of 33 patients with ASB received antibiotic treatment, predominantly β-lactams. All patients received surgical antibiotic prophylaxis; routine prophylaxis changed from cefazolin in 2011 to cefuroxime in 2012, with prophylaxis duration extended to 48 hours. SSI was identified using CDC criteria and classified by location and depth. Surveillance included inpatient follow-up and a telephone call 30 days after discharge. Multivariable logistic regression evaluated the association of ASB, treated UTI, and antibiotic exposure with SSI while accounting for recognized SSI risk factors. Organisms and resistance profiles from urine and SSI cultures were compared.

Duration

March 2011 to April 2015

Outcome Measures

Primary: Association between bacteriuria or UTI and SSI

Secondary: Role of known risk factors for SSI, exposure to antibiotics before the procedure, and phenotypic relationships between pathogens in urine cultures and infection cultures from the surgical site

Baseline Characteristics

 

Result

Age, years (range)

65 (18-91)

Female

292 (34.8%)

Type of procedure

Coronary revascularization

Valve replacement

Both procedures at the same time

 

581 (69.1%)

301 (35.8%)

42 (5%)

Comorbidities

Diabetes mellitus

Heart failure

Renal failure

Chronic obstructive pulmonary disease

 

191 (22.7%)

67 (7.9%)

86 (10.2%)

85 (10.1%)

Tobacco use

119 (14.1%)

Previous cardiac surgery

15 (1.7%)

Infective endocarditis before surgery

17 (10%)

Average prior stay, days (range)

5.3 (0-49)

Stay >7 days

304 (36.1%)

Postoperative intensive care unit stay >3 days

613 (72.9%)

Use of antibiotics before surgery

59 (7%)

Prophylactic antibiotics

840 (100%)

Intraoperative transfusion

308 (36.6%)

Reoperation because of bleeding

27 (3.2%)

Duration of surgery, min (range)

231 (20-540)

Duration >300 min

133 (15.8%)
Results

Postoperative surgical site infection (SSI) occurred in 80 of 840 patients (9.5%), including 56 sternotomy infections (6.6%) and 24 saphenous donor-site infections (2.8%).

In multivariable analysis, neither preoperative asymptomatic bacteriuria (ASB; adjusted risk ratio [RR] 0.83; 95% confidence interval [CI] 0.26–2.56; p= 0.74), treated symptomatic urinary tract infection (adjusted RR 2.54; 95% CI 0.60–10.69; p= 0.20), nor previous antibiotic exposure (adjusted RR 1.70; 95% CI 0.71–4.03; p= 0.22) was significantly associated with SSI.

Among patients with ASB, SSI occurred in 3 of 7 patients receiving preoperative antibiotic treatment (42.8%) and 1 of 26 untreated patients (3.8%); a direct statistical comparison between these subgroups was not reported.

No cases had identical organisms isolated from preoperative urine and postoperative SSI cultures.

Postoperative endocarditis outcomes were not reported.

Adverse Events

Not applicable as the study focused on the association between bacteriuria and SSI, not on adverse events.

Study Author Conclusions

Our study did not identify bacteriuria as a risk factor for post operative infection in cardiovascular surgery. Treatment of UTIs and exposure to antibiotics tend to increase the risk without achiev ing statistically significant benefit. Despite being routine clinical practice, the search for and treatment of asymptomatic bacteri uria in patients who are scheduled to undergo cardiovascular procedures do not seem beneficial in terms of SSI reduction. We do not recommend screening patients via urinalysis or urine culture unless there are urinary symptoms and suspicion of a UTI requir ing treatment. A randomized clinical trial is required to verify these findings and provide recommendations based on high-quality evidence.

Critique

Structured SSI surveillance, adjustment for established risk factors, and comparison of urine and wound organisms strengthen the study; however, selective urine culturing, the small ASB subgroup, nonrandomized treatment, and wide confidence intervals limit conclusions about screening and treatment effectiveness. The study did not demonstrate an association between ASB and SSI, but it cannot establish the effect of ASB treatment on future endocarditis because that outcome was not reported.

Table 3 References:
[6] Duarte JC, Reyes P, Bermdez D, Alzate JP, Maldonado JD, Corts JA. Bacteriuria is not associated with surgical site infection in patients undergoing cardiovascular surgery. Am J Infect Control. 2018;46(2):180-185. doi:10.1016/j.ajic.2017.08.015

Practice Variation in Treatment of Suspected Asymptomatic Bacteriuria Prior to Cardiac Surgery: Are There Differences in Postoperative Outcome? A Retrospective Cohort Study

Design

Retrospective cohort study

N= 1002

Objective

To examine current preoperative practice in treating asymptomatic bacteriuria in cardiothoracic surgery patients and its relation to postoperative outcomes

Study Groups

AB+ (treated with antibiotics) (n= 39)

AB− (not treated with antibiotics) (n= 963)

Inclusion Criteria

Patients who underwent cardiothoracic surgery between 2011 and 2013 using extracorporeal circulation, with preoperative nitrituria and/or leucocyturia

Exclusion Criteria

C-reactive protein level higher than 10 mg/l, emergency surgery, critical preoperative state, and/or antibiotic treatment for other infections

Methods

Urine was routinely screened for nitrite and leucocytes the day before surgery. Antibiotic treatment for suspected bacteriuria was considered in consultation with a microbiologist; urine culture results generally became available postoperatively. Patients were grouped according to preoperative antibiotic prescriptions. Treatment was not standardized; nitrofurantoin was the most frequently prescribed agent (26/39 patients). All patients received perioperative cefazolin 2 g IV, with an additional 1 g if surgery exceeded 4 hours; when prosthetic material was implanted, cefazolin was repeated five times during the first 40 postoperative hours. An indwelling urinary catheter was inserted aseptically before surgery. Surgical database records were linked to laboratory, admission, and pharmacy records; discharge letters resolved discrepancies concerning infectious complications. Preoperative urine and postoperative infection-site cultures were compared to assess possible hematogenous spread. Logistic regression evaluated postoperative infections, with the principal adjusted analysis controlling for EuroSCORE. Postoperative length of stay was evaluated using Kaplan–Meier and Cox proportional hazards analyses; patients who died or transferred to another hospital were censored.

Duration

January 2011 to December 2013

Outcome Measures

Primary: Postoperative infections

Secondary: Length of postoperative hospital stay

Baseline Characteristics  

AB+ (n= 39)

AB− (n= 963)
Age, years

72.7 ± 8.9

69.6 ± 10.1
Female

33 (84.6%)

644 (66.9%)
Body mass index, kg/m2

27.7 ± 4.0

27.3 ± 4.7
Isolated coronary artery bypass grafting

13 (33.3%)

358 (37.2%)
Aortic valve surgery

14 (35.9%)

368 (38.2%)
Thoracic aortic surgery, isolated or combined

6 (15.4%)

111 (11.5%)
EuroSCORE

6.8 ± 2.7

5.9 ± 2.6
Nitrituria

32 (82.1%)

59 (6.1%)
Leucocyturia

38 (97.4%)

955 (99.2%)
Results  

AB+ (n= 39)

AB− (n= 963) p-value
Postoperative infections

2 (5.1%)

80 (8.3%) 0.48
UTI, including patients with multiple infections

1 (2.6%)

30 (3.1%) 0.85
Length of stay, median days

9.76

9.57 0.54

Among antibiotic-treated patients (AB+), 33/39 (84.6%) had positive preoperative urine cultures, whereas 6/39 (15.4%) received treatment despite no significant growth or possible contamination, which the authors considered unnecessary.

Among 80 untreated patients (AB−) with postoperative infections, 26 (32.5%) had positive preoperative urine cultures; no postoperative infection outside the urinary tract was caused by the same microorganism identified preoperatively, and 20/26 had early postoperative urine cultures showing <1,000 microorganisms/mL.

The two postoperative infections in the AB+ group—a UTI and a vascular prosthesis infection—were caused by organisms different from the preoperative urinary organisms and not susceptible to the nitrofurantoin administered. The single AB− patient with postoperative Escherichia coli urosepsis had <100 microorganisms/mL in the preoperative urine culture; no untreated patient with preoperative urinary E. coli developed postoperative urosepsis.

Early valve endocarditis occurred in one AB− patient and no AB+ patients; no endocarditis-specific comparative analysis or long-term endocarditis outcomes were reported.

Adverse Events

No significant difference in postoperative infections between treated and non-treated groups. No haematogenous spread of bacteria from urinary tract to postoperative infection sites.

Study Author Conclusions

The risk of haematogenous spread of bacteria seems to be non-existent in this large cohort of non-treated patients, under our local clinical practice. Based on this currently best available evidence, it seems therefore safe to not treat patients with asymptomatic bacteriuria prior to cardiothoracic surgery. This could also imply not to perform routine preoperative urine testing.

Critique

The large untreated cohort and comparison of urinary and postoperative infection-site organisms strengthen assessment of possible urinary-source infections; however, treatment selection was nonrandomized, only 39 patients received treatment, and enrollment relied on urinalysis rather than culture-confirmed asymptomatic bacteriuria. Universal perioperative cefazolin, exclusion of patients with CRP >10 mg/L, and the absence of a screening-versus-no-screening comparison limit applicability; one early endocarditis event without long-term surveillance cannot establish whether screening or treatment reduces future endocarditis risk.

Table 4 References:
[7] de Lange MP, Sonker U, Kelder JC, de Vos R. Practice variation in treatment of suspected asymptomatic bacteriuria prior to cardiac surgery: are there differences in postoperative outcome? A retrospective cohort study. Interact Cardiovasc Thorac Surg. 2016;22(6):769-775. doi:10.1093/icvts/ivw039

 

Urine Screening Prior to Surgical Valve Replacement: Should It Be Performed?

Design

Single-center retrospective study; abstract only 

N= 358

Objective To identify whether an association exists between asymptomatic bacteriuria (ASB) and post-operative infections in patients undergoing surgical valve replacement (SVR)
Study Groups

Patients with ASB (n= 14)

Patients without ASB (n= 282)

Inclusion Criteria Patients who underwent surgical valve replacement between 2016 and 2018
Exclusion Criteria Not specified
Methods Pre-operative urinalyses and cultures were collected, along with symptoms of UTI and antibiotic therapy during the 60-day pre-op period. Post-op infections, antibiotic therapy, development of resistance, 30-day readmission rates, and 30- and 90-day mortality rates were collected up to 3 months post-op. Statistical analysis was performed using Chi-square and Fisher exact tests
Duration 2016 to 2018
Outcome Measures

Association between ASB and post-op infections

Baseline Characteristics   Patients with ASB (n= 14) Patients without ASB (n= 282)
Pre-op UAs performed 14 (100%) 315 (89%)
Positive cultures treated 11 (79%) 0 (0%)
Results   Patients with ASB (n= 14) Patients without ASB (n= 282) p-value
Post-op infection 1 (7%) 32 (11%) 1
30-day readmission rate 1 (7%) 44 (16%) 0.7
90-day mortality rate 0 (0%) 4 (1%) 1
Development of MDROs 9/68 (13%) 15/290 (5%) 0.02
Adverse Events Antibiotic treatment prior to surgery was associated with acquisition of multi-drug-resistant organisms (MDROs).
Study Author Conclusions ASB prior to SVR was not related to post-op infection, and treatment of ASB did not prevent future infection. Antibiotic treatment prior to SVR was associated with the development of MDROs. Urine screening prior to SVR should be avoided.
Critique The study provides valuable insights into the lack of association between ASB and post-op infections, highlighting the potential risks of antibiotic treatment leading to MDROs. However, the single-center retrospective design may limit the generalizability of the findings. Additionally, the exclusion criteria were not specified, which could impact the study's comprehensiveness. 
Table 5 References:
[8] LeVee A, Beaulac K, Doron S. 1444. Urine Screening Prior to Surgical Valve Replacement: Should It Be Performed?. Open Forum Infect Dis. 2019;6(Suppl 2):S527. Published 2019 Oct 23. doi:10.1093/ofid/ofz360.1308